Journal of Peking University(Health Sciences) >
Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease
Received date: 2024-07-09
Online published: 2024-12-18
Supported by
Chongqing Science and Health Joint Traditional Chinese Medicine Research Project(2024ZYQN002)
Copyright
Objective: To detect the serum level of chemokine CXC motif chemokine 10 (CXCL-10) and Krebs von den lungen-6 (KL-6) in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD), and to analyze their correlation with RA-ILD, as well as the significance in RA-ILD. Methods: A total of 169 RA patients were enrolled in the study. According to imaging findings of with and without ILD in high-resolution computed tomography scans of chest, the subjects were divided into RA-ILD group and RA-non-ILD group. According to the inclusion and exclusion criteria, 80 patients in each of the two groups were finally selected. Two groups were matched according to the 1 ∶ 1 ratio using propensity score matching (PSM). The serum CXCL-10 and KL-6 levels were detected by enzyme-linked immunosorbent assay. The clinical features, laboratory data and medications between the two groups were compared after PSM and the correlation between serum levels and clinical parameters were analyzed. Binary Logistic regression was used to analyze the risk factors of ILD in the RA patients, and the predictive value of CXCL-10 and KL-6 in RA-ILD was evaluated. Results: In this study, 49 patients with RA-ILD and 49 patients with RA-non-ILD were selected by PSM. The levels of CXCL-10 and KL-6 in the RA-ILD group [64.36 (34.01, 110.18) ng/L, 360.70 (236.35, 715.05) U/mL] were significantly higher than those in the RA-non-ILD group [29.80 (16.89, 40.55) ng/L, 210.69 (159.98, 255.50) U/mL] (all P < 0.001). The results of correlation analysis showed that the level of serum CXCL-10 was positively correlated with the Warrick score on chest CT (r=0.378, P=0.007) and negatively correlated with the percentage of forced vital capacity to the predicted value (FVC%, r=-0.338, P=0.018). And the level of KL-6 was positively correlated with rheumatoid factor (RF, r=0.296, P=0.039) and negatively correlated with FVC% (r=-0.436, P=0.002) and the percentage of diffusion capacity for carbon monoxide to the predicted value (DLCO%, r=-0.426, P=0.002). Both univariate and multivariate Logistic regression analysis showed that CXCL-10 and KL-6 were positively correlated with ILD, the values of OR were 1.035 and 1.023 in CXCL-10 and those were 1.004 and 1.005 in KL-6 respectively (P < 0.05). The ROC curves were plotted with CXCL-10 and KL-6. The area under the curve (AUC) was 0.770 and 0.752 respectively. The AUC of combined detection increased to 0.800. Conclusion: Serum levels of CXCL-10 and KL-6 are significantly elevated in patients with RA-ILD and correlated with the severity of ILD. The combined estimate of them helps to improve the effectiveness of diagnosis.
Rui YAN , Dan KE , Yan ZHANG , Li LI , Huanran SU , Wei CHEN , Mingxia SUN , Xiaomin LIU , Liang LUO . Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease[J]. Journal of Peking University(Health Sciences), 2024 , 56(6) : 956 -962 . DOI: 10.19723/j.issn.1671-167X.2024.06.003
| 1 | Kakutani T , Hashimoto A , Tominaga A , et al. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease[J]. Mod Rheumatol, 2020, 30 (3): 458- 464. |
| 2 | Zamora-Legoff JA , Krause ML , Crowson CS , et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis[J]. Rheumatology (Oxford), 2017, 56 (3): 344- 350. |
| 3 | Natalini JG , Swigris JJ , Morisset J , et al. Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease[J]. Respir Med, 2017, 127, 1- 6. |
| 4 | McDermott GC , Doyle TJ , Sparks JA . Interstitial lung disease throughout the rheumatoid arthritis disease course[J]. Curr Opin Rheumatol, 2021, 33 (3): 284- 291. |
| 5 | Raimundo K , Solomon JJ , Olson AL , et al. Rheumatoid arthritis-interstitial lung disease in the United States: Prevalence, incidence, and healthcare costs and mortality[J]. J Rheumatol, 2019, 46 (4): 360- 369. |
| 6 | Shimizu S , Yoshinouchi T , Niimi T , et al. Differing distributions of CXCR3- and CCR4-positive cells among types of interstitial pneumonia associated with collagen vascular diseases[J]. Virchows Arch, 2007, 450 (1): 51- 58. |
| 7 | Kameda M , Otsuka M , Chiba H , et al. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features[J]. PLoS One, 2020, 15 (11): e0241719. |
| 8 | Kim HC , Choi KH , Jacob J , et al. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease[J]. PLoS One, 2020, 15 (3): e0229997. |
| 9 | Raghu G , Rochwerg B , Zhang Y , et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline[J]. Am J Respir Crit Care Med, 2015, 192 (2): e3- e19. |
| 10 | Warrick JH , Bhalla M , Schabel SI , et al. High resolution com-puted tomography in early scleroderma lung disease[J]. J Rheumatol, 1991, 18 (10): 1520- 1528. |
| 11 | Shin S , Park EH , Kang EH , et al. Sex differences in clinical characteristics and their influence on clinical outcomes in an observational cohort of patients with rheumatoid arthritis[J]. Joint Bone Spine, 2021, 88 (3): 105124. |
| 12 | Kronzer VL , Westerlind H , Alfredsson L , et al. Respiratory diseases as risk factors for seropositive and seronegative rheumatoid arthritis and in relation to smoking[J]. Arthritis Rheumatol, 2021, 73 (1): 61- 68. |
| 13 | Kiely P , Busby AD , Nikiphorou E , et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts[J]. BMJ Open, 2019, 9 (5): e028466. |
| 14 | Paulin F , Secco A , Benavidez F , et al. Lung involvement prevalence in patients with early rheumatoid arthritis without known pulmonary disease: A multicentric cross sectional study[J]. Adv Rheumatol, 2021, 61 (1): 52. |
| 15 | Ke Y , Dai X , Xu D , et al. Features and outcomes of elderly rheumatoid arthritis: Does the age of onset matter? A comparative study from a single center in China[J]. Rheumatol Ther, 2021, 8 (1): 243- 254. |
| 16 | Samhouri BF , Vassallo R , Achenbach SJ , et al. Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial lung disease: A population-based cohort[J]. Arthritis Care Res (Hoboken), 2022, 74 (12): 2042- 2049. |
| 17 | Duarte AC , Porter JC , Leandro MJ . The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment[J]. Rheumatology (Oxford), 2019, 58 (11): 2031- 2038. |
| 18 | McFarlane IM , Zhaz SY , Bhamra MS , et al. Assessment of interstitial lung disease among black rheumatoid arthritis patients[J]. Clin Rheumatol, 2019, 38 (12): 3413- 3424. |
| 19 | Hyldgaard C , Hilberg O , Pedersen AB , et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: Comorbidity and mortality[J]. Ann Rheum Dis, 2017, 76 (10): 1700- 1706. |
| 20 | Meyer KC . Pulmonary fibrosis, part Ⅰ: Epidemiology, patho-genesis, and diagnosis[J]. Expert Rev Respir Med, 2017, 11 (5): 343- 359. |
| 21 | King TE Jr , Bradford WZ , Castro-Bernardini S , et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370 (22): 2083- 2092. |
| 22 | Mollica Poeta V , Massara M , Capucetti A , et al. Chemokines and chemokine receptors: New targets for cancer immunotherapy[J]. Front Immunol, 2019, 10, 379. |
| 23 | Pandya JM , Lundell AC , Andersson K , et al. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker[J]. Arthritis Res Ther, 2017, 19 (1): 20. |
| 24 | Yu R , Liu X , Deng X , et al. Serum CHI3L1 as a biomarker of interstitial lung disease in rheumatoid arthritis[J]. Front Immunol, 2023, 14, 1211790. |
| 25 | 吴雪, 武丽君, 罗采南, 等. 涎液化糖链抗原-6在结缔组织病相关间质性肺病诊断中的应用价值[J]. 中华医学杂志, 2019, 99 (40): 3172- 3175. |
| 26 | Lee YS , Kim HC , Lee BY , et al. The value of biomarkers as predictors of outcome in patients with rheumatoid arthritis-associated usual interstitial pneumonia[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2016, 33 (3): 216- 223. |
| 27 | Chen F , Lu X , Shu X , et al. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: A comparative and prospective study[J]. Intern Med J, 2015, 45 (6): 641- 647. |
/
| 〈 |
|
〉 |